FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Andrew Palmer

Research Profile

Disorders

Activities & Behaviors

Concepts & Ideas

Chemicals & Drugs

Co-author Network

Publications

TOP 3
William J Valentine; Morten Lammert; Jakob Langer; Andrew J Palmer; Michael Brändle
Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
Peter Gaede; William J Valentine; Andrew J Palmer; Daniel M D Tucker; Morten Lammert; Hans-Henrik Parving; Oluf Pedersen
Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study.
Michael E Minshall; Alan K Oglesby; Matthew Wintle; William J Valentine; Stéphane Roze; Andrew J Palmer
Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Andrew Palmer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: William J Valentine; Morten Lammert; Jakob Langer; Andrew J Palmer; Michael Brändle
Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
Clinical therapeutics 2011;33(11):1698-712.
2008: Peter Gaede; William J Valentine; Andrew J Palmer; Daniel M D Tucker; Morten Lammert; Hans-Henrik Parving; Oluf Pedersen
Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study.
Diabetes care 2008;31(8):1510-5.
2008: Michael E Minshall; Alan K Oglesby; Matthew Wintle; William J Valentine; Stéphane Roze; Andrew J Palmer
Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2008;11(1):22-33.
2007: Joshua A Ray; William J Valentine; Andrew J Palmer
Cost-utility analysis of cinacalcet in addition to standard of care in the UK.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2007;22(11):3355-7; author reply 3357-8.
2007: Andrew J Palmer; William J Valentine; Joshua A Ray
Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.
International journal of clinical practice 2007;61(10):1626-33.
2007: Todd Gilmer; Stéphane Roze; William J Valentine; Katrina Emy-Albrecht; Joshua A Ray; David Cobden; Lars Nicklasson; Athena Philis-Tsimikas; Andrew J Palmer
Cost-effectiveness of diabetes case management for low-income populations.
Health services research 2007;42(5):1943-59.
2007: William J Valentine; J M Bottomley; Andrew J Palmer; Michael Brändle; Volker Foos; R Williams; J A Dormandy; J Yates; Meng Tan; Massimo Massi Benedetti
PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
Diabetic medicine : a journal of the British Diabetic Association 2007;24(9):982-1002.
2007: Andrew J Palmer; William J Valentine; Joshua A Ray; Stéphane Roze; Noemi Muszbek
Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis.
The European journal of health economics : HEPAC : health economics in prevention and care 2007;8(2):161-8.
2007: Andrew J Palmer; William J Valentine; Joshua A Ray; Volker Foos; Francesco M Lurati; Inger Smith; Morten Lammert; Stéphane Roze
An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK.
Current medical research and opinion 2007;23(4):895-901.
2007: William J Valentine; K M Erny-Albrecht; Joshua A Ray; Stéphane Roze; David Cobden; Andrew J Palmer
Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States.
Advances in therapy 2007;24(2):273-90.
2007: Joshua A Ray; Kristina S Boye; Nicole Yurgin; William J Valentine; Stéphane Roze; Jan McKendrick; Daniel M D Tucker; Volker Foos; Andrew J Palmer
Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
Current medical research and opinion 2007;23(3):609-22.
2007: Neale Cohen; Michael E Minshall; Lyn Sharon-Nash; Katerina Zakrzewska; William J Valentine; Andrew J Palmer
Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.
PharmacoEconomics 2007;25(10):881-97.
2007: Joshua A Ray; William J Valentine; Stéphane Roze; Lars Nicklasson; David Cobden; P Raskin; A Garber; Andrew J Palmer
Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
Diabetes, obesity & metabolism 2007;9(1):103-13.
2006: Andrew J Palmer; William J Valentine; Daniel M D Tucker; Joshua A Ray; Stéphane Roze; Lieven Annemans; Pablo Lapuerta; Roland Chen; Sylvie Gabriel; Paulo Carita; Roger A Rodby; Dick de Zeeuw; Hans-Henrik Parving; Maurice Laville
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
Current medical research and opinion 2006;22(11):2095-100.
2006: William J Valentine; Andrew J Palmer; Lars Nicklasson; David Cobden; Stéphane Roze
Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets.
International journal of clinical practice 2006;60(9):1138-45.
2006: Andrew J Palmer; Stéphane Roze; Roger A Rodby; William J Valentine; E Ritz; H Lehnert
[Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].
Deutsche medizinische Wochenschrift (1946) 2006;131(31-32):1721-6.
2006: Stéphane Roze; William J Valentine; Thomas Evers; Andrew J Palmer
Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting.
Current medical research and opinion 2006;22(7):1415-24.
2006: Andrew J Palmer; Stéphane Roze; William J Valentine; Joshua A Ray; Andreas Frei; Michel Burnier; Bernhard Hess; Giatgen A Spinas; Michael Brändle
Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
Swiss medical weekly 2006;136(21-22):346-52.
2006: Craig J Currie; Phil McEwan; Chris Poole; William J Valentine; Andrew J Palmer; Morten Lammert; Lars Nicklasson; Volker Foos; Stéphane Roze
Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.
Current medical research and opinion 2006;22(5):967-9; author reply 968-9.
2006: A Frei; Andrew J Palmer; M Burnier; B Hess
[Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].
Praxis 2006;95(11):401-8.
2006: William J Valentine; Andrew J Palmer; Katrina M Erny-Albrecht; Joshua A Ray; David Cobden; Volker Foos; Francesco M Lurati; Stéphane Roze
Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH.
Advances in therapy 2006;23(2):191-207.
2006: Daniel M D Tucker; Andrew J Palmer; William J Valentine; Stéphane Roze; Joshua A Ray
Counting the costs of overweight and obesity: modeling clinical and cost outcomes.
Current medical research and opinion 2006;22(3):575-86.
2006: Andrew J Palmer; R Chen; W J Valentine; Stéphane Roze; B Bregman; N Mehin; S Gabriel
Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes.
Diabetes & metabolism 2006;32(1):69-76.
2005: William J Valentine; Andrew J Palmer; Morten Lammert; Lars Nicklasson; Volker Foos; Stéphane Roze
Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.
Current medical research and opinion 2005;21(12):2063-71.
2005: Andrew J Palmer; Daniel M D Tucker; Joshua A Ray; William J Valentine; Craig Currie; Phil McEwan; Michael Brändle
Insulin pumps: more consultation was needed.
BMJ (Clinical research ed.) 2005;331(7521):905-6.
2005: Joshua A Ray; William J Valentine; Kristina Secnik; Alan Oglesby; Anna Cordony; Adam Gordois; Peter Davey; Andrew J Palmer
Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain.
Current medical research and opinion 2005;21(10):1617-29.
2005: Stéphane Roze; William J Valentine; K E Zakrzewska; Andrew J Palmer
Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK.
Diabetic medicine : a journal of the British Diabetic Association 2005;22(9):1239-45.
2005: Michael E Minshall; Stéphane Roze; Andrew J Palmer; William J Valentine; Volker Foos; Joshua Ray; Claudia Graham
Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States.
Clinical therapeutics 2005;27(6):940-50.
2005: Andrew J Palmer; Daniel M D Tucker; William J Valentine; Stéphane Roze; Sylvie Gabriel; Daniel J Cordonnier
Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2005;20(6):1103-9.
2005: Andrew J Palmer; William J Valentine; Stéphane Roze; Morten Lammert; Julie Spiesser; Sylvie Gabriel
Overview of costs of stroke from published, incidence-based studies spanning 16 industrialized countries.
Current medical research and opinion 2005;21(1):19-26.
2005: Andrew J Palmer; Lieven Annemans; Stéphane Roze; Pablo Lapuerta; Roland Chen; Sylvie Gabriel; Paulo Carita; Roger A Rodby; Dick de Zeeuw; Hans-Henrik Parving; Fernando de Alvaro
Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria.
Kidney international. Supplement 2005;(93):S52-4.
2004: Andrew J Palmer; Stéphane Roze; W J Valentine; G Spinas
The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes: response to Scuffham [corrected] and Carr.
Diabetic medicine : a journal of the British Diabetic Association 2004;21(12):1372; author reply 1372-3.
2004: Andrew J Palmer; Stéphane Roze; William J Valentine; Inger Smith; Kim U Wittrup-Jensen
Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
Current medical research and opinion 2004;20(11):1729-46.
2004: Andrew J Palmer; Roger A Rodby
Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria.
Kidney international. Supplement 2004;(92):S118-20.
2004: Andrew J Palmer; Lieven Annemans; Stéphane Roze; Mark Lamotte; Roger A Rodby; R W Bilous
An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.
Journal of human hypertension 2004;18(10):733-8.
2004: Andrew J Palmer; Stéphane Roze; William J Valentine; Michael E Minshall; Morten Lammert; Lars Nicklasson; Giatgen A Spinas
Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy.
Current medical research and opinion 2004;20 Suppl 1():S67-73.
2004: Andrew J Palmer; Stéphane Roze; William J Valentine; Michael E Minshall; Morten Lammert; Alan Oglesby; Clarice Hayes; Giatgen A Spinas
What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model.
Current medical research and opinion 2004;20 Suppl 1():S59-66.
2004: Andrew J Palmer; Stéphane Roze; William J Valentine; Michael E Minshall; Clarice Hayes; Alan Oglesby; Giatgen A Spinas
Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model.
Current medical research and opinion 2004;20 Suppl 1():S53-8.
2004: Andrew J Palmer; Stéphane Roze; Morten Lammert; William J Valentine; Michael E Minshall; Lars Nicklasson; Mari-Anne Gall; Giatgen A Spinas
Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.
Current medical research and opinion 2004;20 Suppl 1():S41-51.
2004: Andrew J Palmer; Stéphane Roze; William J Valentine; Michael E Minshall; Volker Foos; Francesco M Lurati; Morten Lammert; Giatgen A Spinas
Validation of the CORE Diabetes Model against epidemiological and clinical studies.
Current medical research and opinion 2004;20 Suppl 1():S27-40.
2004: Andrew J Palmer; Stéphane Roze; William J Valentine; Michael E Minshall; Volker Foos; Francesco M Lurati; Morten Lammert; Giatgen A Spinas
The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
Current medical research and opinion 2004;20 Suppl 1():S5-26.
2004: Andrew J Palmer; Lieven Annemans; Stéphane Roze; Mark Lamotte; Pablo Lapuerta; Roland Chen; Sylvie Gabriel; Paulo Carita; Roger A Rodby; Dick de Zeeuw; Hans-Henrik Parving
Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
Diabetes care 2004;27(8):1897-903.
2004: Andrew J Palmer; Stéphane Roze; William J Valentine; Giatgen A Spinas; Jonathan E Shaw; Paul Z Zimmet
Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom.
Clinical therapeutics 2004;26(2):304-21.
2004: Andrew J Palmer; Lieven Annemans; Stéphane Roze; Mark Lamotte; Roger A Rodby; E Ritz
[Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
Deutsche medizinische Wochenschrift (1946) 2004;129(1-2):13-8.
2004: Andrew J Palmer; Lieven Annemans; Stéphane Roze; Mark Lamotte; Roger A Rodby; Fernando de Alvaro
[Cost-efectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective].
Nefrología : publicación oficial de la Sociedad Española Nefrologia 2004;24(3):231-8.
2003: Andrew J Palmer; Lieven Annemans; Stéphane Roze; Mark Lamotte; Roger A Rodby; Daniel J Cordonnier
An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2003;18(10):2059-66.
2003: Roger A Rodby; Chion Fang Chiou; Jeff Borenstein; Allison L Smitten; Nishan Sengupta; Andrew J Palmer; Stéphane Roze; Lieven Annemans; teresa simon; Roland S Chen; Edmund J Lewis
The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.
Clinical therapeutics 2003;25(7):2102-19.
2003: Stéphane Roze; Andrew J Palmer; William J Valentine
A multivariate logistic regression equation to screen for diabetes: response to Tabaei and Herman.
Diabetes care 2003;26(5):1658-9; author reply 1659.